 The purpose of this study is to evaluate the safety, tolerability, immune response and clinical efficacies of HLA-A2402 or HLA-A0201 restricted epitope peptides VEGF-R1 and VEGF-R2 emulsified with Montanide ISA 51 for advanced solid tumors. 